Phase 2 N=36 RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
Prostate Cancer
Primary: Overall Response Rate — 6 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,224 Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Prostatic Neoplasms · Neoplasm Metastasis
Primary: Overall Survival Time — 21.22; 22.14 months — p=0.3802
Phase 2 N=62 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Prostate Cancer
Primary: Progression Free Survival — 16.1 months
Phase 2 N=18 Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response Rate — 6 Participants
Phase 2 N=19 Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage III Prostate Cancer
Primary: Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria — 5; 3 Participants — p=0.46
Phase 2 N=10 Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients
Phase 3 N=790 Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer
Primary: Overall Survival — 57.6; 44.0 months — p=0.0003
Phase 2 N=73 Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
Prostatic Neoplasms
Primary: Number of Participants Who Had a Prostate-specific Antigen (PSA) Response — 52 Participants
Phase 3 N=1,038 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
Metastatic Cancer · Prostate Cancer
Primary: Compare Survival Between a Control or Standard Therapy Arm of Docetaxel + Placebo + Prednisone With Docetaxel + Atrasentan + Prednisone in Patients With Hormone…
Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
N/A N=20 Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline
Phase 2 N=30 Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Hormone-Resistant Prostate Cancer · Metastatic Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg
Phase 2 N=39 Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer
Prostate Cancer
Primary: Maximum Tolerated Dose and Toxicity Profile
Phase 2 N=41 Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Composite Time to Disease Progression (cTTP) for Participants Treated With Cixutumumab — 4.9; 3.2 months
Phase 2 N=138 A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
Prostate Cancer
Primary: Composite Progression-free Survival (cPFS) — 4.1; 6.7 months
Phase 2 N=45 Radiation and Androgen Ablation for Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Biochemical Failure Free-rate (BFFR) Associated With the Combined Hypofractionated Dose Regimen and Androgen Deprivation Therapy (ADT). — 0 progression events
Phase 2 N=71 Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Prostate Cancer · Neoplasm Metastasis
Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants
Phase 3 N=1,279 S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 81.1; 70.2 months — p=.080
Phase 2 N=36 AMG 386 and Abiraterone for Advanced Prostate Cancer
Prostatic Neoplasms · Prostate Cancer · Neoplasm, Prostate
Primary: Progression Free Survival (PFS) — 2.8; 9.0; 11.5; 10.1 Months — p=0.44
Phase 2 N=19 The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
Metastatic, Androgen Independent Prostate Cancer · Prostate Cancer
Primary: Number of Patients Free of Dose Limiting Toxicity — 14 participants
Phase 2 N=90 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Prostate Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale
Phase 2 N=41 Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
Prostate Cancer
Primary: Metabolic Syndrome — 0; 0 kilograms
Phase 2 N=29 Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
Prostate Cancer
Primary: Overall Clinical Benefit of Tarceva in CRPC. — 36 percentage of pts w/clinical benefit
Phase 2 N=115 Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
Androgen-independent Prostate Cancer
Primary: Median Time to Progression (TTP) — 4.9; 6.6 Months
Phase 2 N=59 AZD2171 to Treat Prostate Cancer
Prostate Cancer
Primary: Percent Probability of Participants With 6-month Progression-free Survival (PFS) — 43.9 percent probability
Phase 2 N=22 Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients Needing a Dose Reduction. — 71 percentage of participants
Phase 2 N=37 Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients With Undetectable PSA (Prostate-Specific Antigen) at 1 Year — 54.54 percentage of participants
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=46 A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
Prostate Cancer
Primary: Progression Free Survival — 1.83; 3.7 months
Phase 2 N=36 Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…